Sophia Antipolis, France

Press release – For immediate release – 5:45 pm CET

Median Technologies meets the eligibility conditions for the PEA-PME scheme

Median Technologies (FR0011049824, ALMDT) confirms its eligibility for the PEA-PME scheme in accordance with the provisions of Articles L. 221-32-2 and D. 221-113-5 and following of the Monetary and Financial Code specifying the conditions for assessing the eligibility criteria, i.e.:

  • Less than 5,000 employees,
  • An annual turnover of less than 1.5 billion euros or a balance sheet total of less than 2 billion euros.

Median Technologies shares therefore continue to be included in PEA-PME accounts, which for the record benefit from the same tax advantages as the traditional stock savings plan (PEA).

Download 202409313_PR_PEAPME_EN.pdf

About Median Technologies

Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit


Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24